Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05599347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease

Study acronym: AZITRATIM
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2026 (before its estimated September 10, 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 8 months later Dec 31, 2025 → Sep 10, 2026
See other at-risk trials from Rambam Health Care Campus

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2025 to Sep 10, 2026
    • Study completion pushed from Dec 31, 2026 to Sep 10, 2027
    • Site details revised at 1 of 9 sites
    v4
  2. Study sites: 11 to 9v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date changed from estimate of Jan 1, 2023 to Apr 24, 2023
    • Study sites: 1 to 11
    • Eligibility criteria expanded, about 214 words
    • Secondary endpoints: 6 to 12
    • Study title shortened, about 2 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized placebo-controlled trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity
Trial Details
NCT Number NCT05599347
Lead Sponsor Rambam Health Care Campus
Conditions
(from sponsor)		 Crohn's Disease Relapse, Biological Substance; Adverse Effect
Related terms Crohn Disease
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov